Erratum: The ORION Study: Comparison of Two Sirolimus-Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients (American Journal of Transplantation (2011) 11(8) (1633–1644), (S1600613522270129), (10.1111/j.1600-6143.2011.03573.x));The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

American Journal of Transplantation

Volumn 11, Issue 8, 2011, Pages 1633-1644

  Flechner, S M ^a   Glyda, M ^b   Cockfield, S ^c   Grinyo J ^d   Legendre, Ch ^e   Russ, G ^f   Steinberg, S ^g   Wissing, K M ^h   Tai, S S ⁱ  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Szpital Wojewodzki   (Poland)

^c UNIVERSITY OF ALBERTA   (Canada)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f QUEEN ELIZABETH HOSPITAL   (Australia)

^g SHARP MEMORIAL HOSPITAL   (United States)

^h ERASME HOSPITAL   (Belgium)

ⁱ PFIZER INC   (United States)

Author keywords

Acute allograft rejection; delayed graft function (DGF); mycophenolate mofetil; renal function; sirolimus; tacrolimus

Indexed keywords

DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACNE; ADULT; ANEMIA; ARTICLE; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY CANCER; KIDNEY TRANSPLANTATION; LYMPHOCELE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; UROGENITAL TRACT CANCER; WOUND HEALING IMPAIRMENT;

EID: 79961032806     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03939.x     Document Type: Erratum

References (31)

1. Bennett WM,. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996; 34: 515-519. (Pubitemid 26386039)
2. Pescovitz MD, Govani M,. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. Am J Kidney Dis 2001; 38 (4 Suppl 2): S16-S21. (Pubitemid 32916885)
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333. (Pubitemid 37509740)
4. Groth CG, Backman L, Morales JM, et al,. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042. (Pubitemid 29200856)
5. Kreis H, Cisterne JM, Land W, et al,. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-1260. (Pubitemid 30238708)
6. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT,. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040-1046. (Pubitemid 28513384)
7. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J,. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune study group. Transplantation 1999; 68: 1526-1532.
8. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, for the Sirolimus Renal Function Study Group. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560-1567. (Pubitemid 36014229)
9. Baboolal K., A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (Rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003; 75: 1404-1410.
10. Stallone G, Di PS, Schena A, et al,. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003; 75: 998-1003. (Pubitemid 36438529)
11. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J,. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786. (Pubitemid 32879845)
12. Oberbauer R, Kreis H, Johnson RWG, et al,. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364-370. (Pubitemid 36928000)
13. Oberbauer R, Segoloni G, Campistol JM, et al,. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22-28. (Pubitemid 41742941)
14. Grinyo JM, Campistol JM, Paul J, et al,. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004; 4: 1308-1314. (Pubitemid 39013578)
15. Flechner SM, Goldfarb D, Modlin C, et al,. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporin. Transplantation 2002; 74: 1070-1076. (Pubitemid 35216097)
16. Flechner SM, Kurian SM, Solez K, et al,. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-1785. (Pubitemid 39434437)
17. Flechner SM, Goldfarb D, Solez K, et al,. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883-892. (Pubitemid 46682728)
18. Larson TS, Dean PG, Stegall MD, et al,. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522. (Pubitemid 43382137)
19. Hamdy AF, Bakr MA, Ghoneim MA,. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J Am Soc Nephrol 2008; 19: 1225-1232.
20. Mulay AV, Hussain N, Fergusson D, Knoll GA,. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 1748-1756. (Pubitemid 40910459)
21. Kahan BD,. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202. (Pubitemid 30446974)
22. MacDonald AS, for the Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/ cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280. (Pubitemid 32126112)
23. Gonwa T, Mendez R, Yang HC, et al,. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 2003; 75: 1213-1220. (Pubitemid 36513023)
24. Buchler M, Caillard S, Barbier S, et al,. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522-2531. (Pubitemid 47561618)
25. Martinez-Mier G, Mendez-Lopez MT, Budar-Fernandez LF, et al,. Living related kidney transplantation without calcineurin inhibitors: Initial experience in a Mexican center. Transplantation 2006; 82: 1533-1536. (Pubitemid 44967639)
26. Glotz D, Charpentier B, Abramovicz D, et al,. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010; 89: 1511-1517.
27. Figueiro JM, Vilaca SS, Gontijo RC, Souza GS,. CNI-free immunosuppression in de novo kidney transplantation [abstract]. Am J Transplant 2007; 7 (Suppl 2): 160.
28. Webster AC, Lee VW, Chapman JR, Craig JC,. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
29. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575. (Pubitemid 350294223)
30. Kasiske BL, de Mattos A, Flechner SM, et al,. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8: 1384-1392. (Pubitemid 351989497)
31. Johnston O, Rose CL, Webster AC, Gill JS,. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418.